Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Epicenter who wrote (6969)	2/9/1999 7:44:00 PM
From: Anthony Wong	Respond to of 9523

Thanks for the report, Epicenter. Great start so far for Celebrex. Today's PFE sell-off is not unexpected, at least by Mr. Peabody, after the recent run-up. To use a cliche, the next few days would present a great buying opportunity for those who trade the stock as well as those taking a new position in PFE.

To: Epicenter who wrote (6969)	2/9/1999 9:27:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Report from the ML conference from labpuppy.com: Pfizer (PFE) – People tried to find out the details about the products that PFE must allow Warner-Lambert (WLA) and Monsanto (MTC) to co-promote since they gave PFE the rights to co-promote Lipitor and Celebrex. PFE was very tight-lipped about this. In regards to Celebrex, they went through their sampling campaign faster than expected (given the strong demand). They think that Celebrex has a better claim than Vioxx as it has a claim for rheumatoid arthritis versus Vioxx's pain claim. They think since that rheumatoid arthritis is a serious arthritis disease, it will boost their claims in the general arthritis market. They are in phase 2 studies on Viagra for women. They will be starting direct-to-consumer advertising in the US in order to "reinvigorate" flat US Viagra sales. labpuppy.com